Clinical Research Directory

Inclusion Criteria: * Women age \> 45 * Postmenopausal by either of the following criteria: (1) \> 36 months since last spontaneous menses; or (2) \> 36 months since hysterectomy, plus serum FSH \> 40 units / liter if \< 60 years * High risk of fracture defined as one of the following: (1) Prior history of osteoporotic fracture, plus hip or spine BMD T-score \< -2.0; (2) Hip or spine BMD T-score \< -2.5; or (3) 10-year predicted fracture risk of ≥20% for major osteoporotic fracture or ≥3% for hip fracture (designated as "high risk of fracture" by osteoporosis guidelines) Exclusion Criteria: * Current or past use in the 12 months of denosumab * Any prior exposure to romosozumab * Current or use in the past 3 months of estrogens or SERMs * Current or use in the past 6 months of oral bisphosphonates (BPs) if most recent duration of oral BP use is less than 3 years; or current or use in the past 12 months of oral BPs if most recent duration of oral BP use is 3 years or more * Current or use in the past 36 months of parenteral BPs * Current or use in the past 24 months of teriparatide or abaloparatide * Use of glucocorticoids for more than 14 days consecutively within the past 6 months